FDA approves first adjuvanted quadrivalent flu vaccine in over-65s

pharmafile | February 24, 2020 | News story | Sales and Marketing FDA, flu, influenza, pharma, seqirus 

The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) has been approved in the US to for the prevention of seasonal vaccine in patients over the age of 65.

The new indication is crucial in seasonal flu; during the US influenza season of 2017/2018, 70% of flu-related hospitalisations occurred in over-65-year-olds, while 90% of flu-related deaths also occurred within this group.

Elderly patients can also experience impaired vaccine efficacy due to age-related decline of the immune system. The Centers for Disease Control and Prevention advise that all patients at least six months old receive an influenza vaccine shot on an annual basis.

This quadrivalent vaccine contains the same MF59 adjuvant technology as its Seqirus’ Fluad vaccine, and also covers an additional strain of influenza.  

“Adults 65 years and older are at high risk for influenza-related complications each season and it is important to have influenza vaccines to help protect this vulnerable population,” commented Anjana Narain, Executive Vice President and General Manager at Seqirus. “As part of our leading role on the front line of influenza prevention, we are pleased to offer Fluad Quadrivalent as another seasonal vaccine option for healthcare providers and their patients in the fight against influenza.”

Matt Fellows


Related Content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …

Biogen’s biosimilar Tofidence approved by FDA

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …


Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …

Latest content